Cellectar Biosciences (CLRB)

Take Impact Assessment
Overall impact
B (79)

Commentary

Cellectar Biosciences is a strong overall performer. With a 'B' rating of 78.7 for overall impact (93rd percentile compared to all companies), Cellectar Biosciences ranks 71st out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 67 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 511 others. On top material causes for Cellectar Biosciences's industry (Pharmaceuticals & Biotech), Cellectar Biosciences performs well in Child and Maternal Health (95.0 score), Access to Affordable Healthcare (95.9), Disease Eradication (96.7) and 5 other causes where it received an 'A' score. Cellectar Biosciences did not receive a 'D' or 'F' rating on any cause.
... read full commentary
Less
Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact
Cause CLRB
Peer rank
Overall impact

Log in to view this information

Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1996
Employees
11
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nj, United States
Share classes
CLRB
More info
https://www.cellectar.com
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. Cellectar has collaborations with Orano Med to develop CLR 12120 Series and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Material causes
Ethos considers the following causes material for Cellectar Biosciences, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.
Access to affordable healthcare
Ensure universal access to affordable, quality healthcare
Accountable institutions
Build accountable and inclusive institutions at all levels
Child and maternal health
End preventable deaths of mothers and children, support reproductive health everywhere
Decent, safe work opportunities
Promote full and productive employment for all, in safe work environments
Disaster readiness and effective aid
Be prepared for natural disasters and provide effective aid when disasters happen
Disease eradication
Eradicate infectious and non-communicable diseases
Equal pay and opportunity
Achieve equal pay and opportunity for women everywhere
Free, secure flow of information
Ensure a free and open flow of information, with secure personal data and privacy
Humane treatment of animals
Ensure humane treatment of animals everywhere
Improved mental health
Support awareness and access to mental health support for all
Quality lifelong education
Ensure access to quality secondary education and lifelong learning opportunities for all
Racial justice and civil rights
Eliminate racism and ensure justice for all
Reduced green house gas emissions
Continually reduce green house gas emissions and other pollutants
Reduced use of tobacco
Continually reduce the use of tobacco
Reduced waste
Reduce waste and support re-usable materials
Sustainable use of natural resources
Ensure sustainable use of natural resources
Sustainable use of water
Promote sustainable management of water everywhere
Technology innovation
Foster technology innovation that supports sustainable economic development
Health and well-being
Ensure healthy lives and promote well-being for all at all ages
Peace and justice
Promote peaceful and inclusive societies, provide access to justice for all
Inclusive economies
Create inclusive economies with no poverty, decent work for all, and affordable living conditions
Climate action
Take urgent action to combat climate change and its impacts
Gender equality
Achieve gender equality and empower all women and girls
Innovation
Innovate to foster economic growth and human development
Life on earth
Protect biodiversity and ensure sustainable use of ecosystems
Quality education
Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all
Sustainable resource use
Ensure sustainable consumption and production patterns
Water and sanitation
Ensure availability and sustainable management of water and sanitation for all

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.
OK
OK, I agree
No thanks